Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia

European Journal of Haematology

Volumn 97, Issue 3, 2016, Pages 253-260

  Maurer, Christian ^a   Pflug, Natali ^a   Bahlo, Jasmin ^a   Kluth, Sandra ^a   Rhein, Christina ^a   Cramer, Paula ^a   Gross Ophoff, Carolin ^a   Langerbeins, Petra ^a   Fink, Anna Maria ^a   Eichhorst, Barbara ^a   Kreuzer, Karl Anton ^a   Fischer, Norbert ^b   Tausch, Eugen ^c   Stilgenbauer, Stephan ^c   Böttcher, Sebastian ^d   Döhner, Hartmut ^c   Kneba, Michael ^d   Dreyling, Martin ^e   Binder, Mascha ^f   Hallek, Michael ^a   Wendtner, Clemens Martin ^a,b   Bergmann, Manuela ^b   Fischer, Kirsten ^a   more..

^a UNIVERSITY OF COLOGNE   (Germany)

^b Klinikum Schwabing   (Germany)

^c UNIVERSITY OF ULM   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

combination treatment with lenalidomide; dose levels; dose limiting toxicity; overall response rate; toxicity

Indexed keywords

BENDAMUSTINE; LENALIDOMIDE; RITUXIMAB;

AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BRONCHITIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ENTEROCOCCAL INFECTION; FEMALE; HUMAN; INFECTION; LUNG INFECTION; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RESPIRATORY TRACT INFECTION; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84982133303     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12714     Document Type: Article

References (31)

1. Dighiero G, Binet JL. Chronic lymphocytic leukemia. Hematol Cell Ther 1996;38(Suppl 2):S41–61.
2. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446–56.
3. Dreger P, Döhner H, Ritgen M, et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 2010;116:2438–47.
4. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079–88.
5. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol Off J Am Soc Clin Oncol 2005;23:4070–8.
6. Robak T, Dmoszynska A, Solal-Céligny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol Off J Am Soc Clin Oncol 2010;28:1756–65.
7. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164–74.
8. Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011;29:3559–66.
9. Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol Off J Am Soc Clin Oncol 2012;30:3209–16.
10. Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol Off J Am Soc Clin Oncol 2006;24:5343–9.
11. Ferrajoli A, Lee B-N, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111:5291–7.
12. Badoux XC, Keating MJ, Wen S, Wierda WG, O'Brien SM, Faderl S, Sargent R, Burger JA, Ferrajoli A. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol Off J Am Soc Clin Oncol 2013;31:584–91.
13. Fecteau J-F, Corral LG, Ghia EM, et al. Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53. Blood 2014;124:1637–44.
14. Krönke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 2014;343:301–5.
15. Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, et al. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res Off J Am Assoc Cancer Res 2005;11:5984–92.
16. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J, Wallace P, Czuczman MS. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 2008;140:36–45.
17. Wendtner C-M, Hillmen P, Mahadevan D, et al. Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma 2012;53:417–23.
18. Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol Off J Am Soc Clin Oncol 1998;16:1582–7.
19. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990–7.
20. Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Hematol Educ Program Am Soc Hematol Am Soc Hematol Educ Program 2013;2013:138–50.
21. Brown JR, Abramson J, Hochberg E, et al. A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL. Leuk Off J Leuk Soc Am Leuk Res Fund UK 2010;24:1972–5.
22. Abramson JS, Davids MS, Werner L, Fisher DC, Armand P, Amrein PC, Neuberg D, Hochberg EP, Brown JR. Lenalidomide added to bendamustine-rituximab for untreated chronic lymphocytic leukemia (CLL): A phase I study. Hematol Oncol Spec Issue 13-ICML 13th Int Conf Malig Lymphoma Palazzo Dei Congr Lugano Switz 17-20 June 2015. 2015 Jun;Volume 33, Issue Supplement S1:106–7.
23. Egle A, Steurer M, Melchardt T, Stoll M, Greil R. The REVLIRIT CLL5 AGMT study - a Phase I/II trial combining fludarabine/rituximab with escalating doses of lenalidomide followed by rituximab/lenalidomide in untreated chronic lymphocytic leukemia (CLL): results of a planned interim analysis. Blood 2009;114:3453–3453.
24. Flinn IW, Berdeja JG, Waselenko JK, et al. Preliminary results from a phase I/II study of fludarabine, rituximab, and lenalidomide in untreated patients with chronic lymphocytic leukemia (CLL). Blood 2010;116:2461–2461.
25. Zaja F, Ferrero S, Stelitano C, et al. Rituximab, Lenalidomide, Bendamustine second line therapy in mantle cell lymphoma: A phase II study of the Fondazione Italiana Linfomi (FIL). Hematol Oncol Spec Issue 13-ICML 13th Int Conf Malig Lymphoma Palazzo Dei Congr Lugano Switz 17-20 June 2015. 2015 Jun;Volume 33, Issue Supplement S1:107.
26. Hitz F, Zucca E, Pabst T, et al. Rituximab, Bendamustine and Lenalidomide in patients with relapsed/refractory aggressive B-cell lymphoma not eligible for salvage chemotherapy. Phase II trial—SAKK 38/08. Hematol Oncol Spec Issue 13-ICML 13th Int Conf Malig Lymphoma Palazzo Dei Congr Lugano Switz 17-20 June 2015. 2015 Jun;Volume 33, Issue Supplement S1:107–8.
27. Albertsson-Lindblad A, Kolstad A, Laurell A, Räty R, Pedersen LB, Sundberg J, Geisler C, Jerkeman M. Lenalidomide-Rituximab-Bendamustine in first line for patients > 65 with mantle cell lymphoma: Final results of the Nordic Lymphoma Group MCL4 (LENA-BERIT) Phase I/II trial. Hematol Oncol Spec Issue 13-ICML 13th Int Conf Malig Lymphoma Palazzo Dei Congr Lugano Switz 17-20 June 2015. 2015 Jun;Volume 33, Issue Supplement S1:131.
28. Eichhorst B, Bahlo J, Fink AM, et al. Good tolerance of lenalidomide maintenance therapy in patients with high risk profile chronic lymphocytic leukemia (CLL) after frontline chemoimmunotherapy: preliminary safety overview of the CLLM1 Trial of the German CLL Study Group (GCLLSG). Blood 2014;124:4699–4699.
29. Hallek M. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. Am J Hematol 2015;90:446–60.
30. Woyach JA, Furman RR, Liu T-M, et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med 2014;370:2286–94.
31. Furman RR, Cheng S, Lu P, et al. Ibrutinib resistance in chronic lymphocytic leukemia. N Engl J Med 2014;370:2352–4.